Published: 11 March 2023
Author(s): Shiping He, Ruofan Li, Shangyi Jin, Yanhong Wang, Hongbin Li, Xinwang Duan, Lili Pan, Lijun Wu, Yongfu Wang, Yan Zhang, Zhenbiao Wu, Jing Li, Yunjiao Yang, Xinping Tian, Xiaofeng Zeng
Issue: May 2023
Section: Original article

Takayasu arteritis (TAK) is a chronic systemic large vessel vasculitis characterized by damage to the aorta and its major branches. TAK primarily occurs in young women in Asia, with a male-to-female ratio of approximately 1:8 [1,2]. Constitutional symptoms of systemic inflammation and vascular complications are the major clinical manifestations of patients with TAK. Despite improved treatment strategies, the majority of patients experience relapses. It is generally accepted that TAK should be treated with immunosuppressive therapy to control acute disease flare and maintain remission [1,3-5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.